Psilocybin Shows Promise for Hard-to-Treat Depression in New Study
Compass Pathways has announced positive top-line results from the first-ever Phase 3 trial of a classic psychedelic for treatment-resistant depression: a single 25-milligram dose of its synthetic psilocybin treatment, COMP360, reduced depression symptoms significantly more than placebo after six weeks in 258 patients across 32 U.S. sites. The company says no unexpected safety issues emerged, and it plans to share further data with the FDA as a parallel trial continues.
Source: The Educated Patient Depression treatment during pregnancy may benefit babies' brain development, randomized trial finds
In the first randomized controlled trial to show that treating prenatal depression can change infant brain structure, mothers who received eight weekly sessions of interpersonal psychotherapy during pregnancy had babies with measurably different hippocampus development — a region tied to emotion and memory — and those differences predicted better emotion regulation at six months of age. The researchers call pregnancy a critical window, noting that supporting maternal mental health may be an early investment in healthy child development.
Source: Medical Xpress Online Sports Betting Linked To Rise In Depression And Anxiety Treatment
A Johns Hopkins study of health insurance records from 2016 to 2023 found that in states that legalized online sports betting, prescriptions for antidepressants and anti-anxiety medications rose by about 5% among adults aged 18 to 64 with employer-sponsored insurance, and outpatient diagnoses of depression and anxiety rose roughly 5 to 7 percent. The authors caution the study doesn't prove sports betting caused the increase, but warn the added demand may be straining the mental health system.
Source: Drugs.com
Compass Pathways has announced positive top-line results from the first-ever Phase 3 trial of a classic psychedelic for treatment-resistant depression: a single 25-milligram dose of its synthetic psilocybin treatment, COMP360, reduced depression symptoms significantly more than placebo after six weeks in 258 patients across 32 U.S. sites. The company says no unexpected safety issues emerged, and it plans to share further data with the FDA as a parallel trial continues.
Source: The Educated Patient Depression treatment during pregnancy may benefit babies' brain development, randomized trial finds
In the first randomized controlled trial to show that treating prenatal depression can change infant brain structure, mothers who received eight weekly sessions of interpersonal psychotherapy during pregnancy had babies with measurably different hippocampus development — a region tied to emotion and memory — and those differences predicted better emotion regulation at six months of age. The researchers call pregnancy a critical window, noting that supporting maternal mental health may be an early investment in healthy child development.
Source: Medical Xpress Online Sports Betting Linked To Rise In Depression And Anxiety Treatment
A Johns Hopkins study of health insurance records from 2016 to 2023 found that in states that legalized online sports betting, prescriptions for antidepressants and anti-anxiety medications rose by about 5% among adults aged 18 to 64 with employer-sponsored insurance, and outpatient diagnoses of depression and anxiety rose roughly 5 to 7 percent. The authors caution the study doesn't prove sports betting caused the increase, but warn the added demand may be straining the mental health system.
Source: Drugs.com